Compare Dishman Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NOVARTIS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NOVARTIS DISHMAN PHARMA/
NOVARTIS
 
P/E (TTM) x 25.1 483.8 5.2% View Chart
P/BV x 3.3 28.1 11.9% View Chart
Dividend Yield % 0.7 1.6 40.8%  

Financials

 DISHMAN PHARMA   NOVARTIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NOVARTIS
Mar-18
DISHMAN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs374758 49.4%   
Low Rs129579 22.3%   
Sales per share (Unadj.) Rs197.8228.4 86.6%  
Earnings per share (Unadj.) Rs21.231.7 66.8%  
Cash flow per share (Unadj.) Rs34.732.8 106.0%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.5 53.1%  
Book value per share (Unadj.) Rs179.9297.1 60.5%  
Shares outstanding (eoy) m80.6924.69 326.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 43.5%   
Avg P/E ratio x11.921.1 56.3%  
P/CF ratio (eoy) x7.220.4 35.5%  
Price / Book Value ratio x1.42.2 62.2%  
Dividend payout %9.431.5 29.9%   
Avg Mkt Cap Rs m20,30616,505 123.0%   
No. of employees `0000.80.7 124.1%   
Total wages/salary Rs m5,3551,445 370.5%   
Avg. sales/employee Rs Th19,252.78,441.3 228.1%   
Avg. wages/employee Rs Th6,459.52,163.6 298.5%   
Avg. net profit/employee Rs Th2,064.11,173.1 176.0%   
INCOME DATA
Net Sales Rs m15,9615,639 283.0%  
Other income Rs m2651,718 15.4%   
Total revenues Rs m16,2267,357 220.5%   
Gross profit Rs m4,103-63 -6,565.1%  
Depreciation Rs m1,09125 4,310.7%   
Interest Rs m94455 1,707.8%   
Profit before tax Rs m2,3341,575 148.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624792 78.8%   
Profit after tax Rs m1,711784 218.4%  
Gross profit margin %25.7-1.1 -2,319.4%  
Effective tax rate %26.750.3 53.2%   
Net profit margin %10.713.9 77.1%  
BALANCE SHEET DATA
Current assets Rs m11,0189,522 115.7%   
Current liabilities Rs m9,5173,296 288.7%   
Net working cap to sales %9.4110.4 8.5%  
Current ratio x1.22.9 40.1%  
Inventory Days Days11037 301.8%  
Debtors Days Days3528 122.6%  
Net fixed assets Rs m16,30446 35,443.7%   
Share capital Rs m161123 130.8%   
"Free" reserves Rs m12,9077,213 178.9%   
Net worth Rs m14,5167,336 197.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80511,105 268.4%  
Interest coverage x3.529.5 11.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 105.5%   
Return on assets %8.97.6 117.9%  
Return on equity %11.810.7 110.4%  
Return on capital %17.522.2 78.9%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95261 8,170.8%   
Fx outflow Rs m6973,630 19.2%   
Net fx Rs m4,255-3,570 -119.2%   
CASH FLOW
From Operations Rs m2,7861,610 173.1%  
From Investments Rs m-1,529687 -222.5%  
From Financial Activity Rs m-941-2,677 35.2%  
Net Cashflow Rs m316-380 -83.4%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 2.0 185.0%  
FIIs % 12.7 1.6 793.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.5 102.8%  
Shareholders   46,261 41,647 111.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FRESENIUS KABI ONCO.  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS